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the end of 1st line CT, at the initiation and completion of second line 
CT and 12 and 18 months post baseline.
Results: 975 patients were enrolled between April 2003 and Sep-
tember 2004, with observations completed in March 2006. Median 
age was 65 yrs (32-90) with 28.3% of pts aged ≥ 70 yrs; 71.3% were 
male; 65.2% had stage IV disease. 487 pts experienced weight loss, 
172 lost >10% body weight in 4 weeks prior to the start of CT (79 
pts, 15.3% unknown). Overall baseline WHO PS was 0 (21.1%), 1 
(65.1%), 2 (10.0%), 3 (3.3%), 4 (0.5%). After 2 cycles of CT, WHO 
PS was unchanged for 57.6% (562) of pts (missing 99 pts); analysis by 
baseline WHO PS showed no change for 90 (44.3%) of pts with PS 0, 
423 (67.6%) PS 1, 32 (33.3%) PS 2, 14 (43.8%) PS 3 and 3 pts (60.0%) 
with baseline PS 4. Median duration of ﬁrst line CT was 3.0 months. At 
the end of 1st line chemotherapy PS was unchanged from baseline for 
41.2% of pts (missing 223 pts, 22.9%). Analysis by baseline PS shows 
no change for 64 (31.5%) of pts with baseline PS 0, 313 (50.0%) PS 1, 
14 (14.6%) PS 2, 9 (28.1%) PS 3, 2 (40%) PS 4. Improvement in PS 
during 1st line CT was seen in 66 (10.5%) of pts with baseline PS 1, 30 
(31.3%) PS 2, 5 (15.6%) PS 3, 2 (40%) PS 4. 285 pts were intended to 
receive 2nd line CT. At initiation of 2nd line CT, overall WHO PS was 
0 (11.3%), 1 (67.5%), 2 (17%), 3 (3.9%), 4 (0.4%). Median duration 
of 2nd line CT was 2.5 months. At the end of 2nd line CT, 254 patients 
had WHO PS 0 (6.8%), 1 (56.2%), 2 (17%), 3 (14.5%), 4 (5.5%) (no 
data 19 pts). 
Conclusion: The administration of CT to patients with PS 0 - 4 was 
recorded in this ﬁrst large-scale observational study of pts with ad-
vanced NSCLC. The majority of patients maintain PS after two cycles 
of 1st line CT. In those pts who received second line CT, a trend toward 
deteriorating PS is seen. The assessment of WHO PS is subjective. 
Maintenance or change in WHO PS may be driven by the impact of the 
cancer, chemotherapy treatment and/or any pre-existing co-morbidities. 
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Background: Preclinical and clinical studies showed that selective 
cyclooxygenase-2 (COX-2) inhibitor (celecoxib or rofecoxib) might 
improve efﬁcacy of treatment of advanced NSCLC. Meloxicam is 
a non-coxib, non-steroidal anti-inﬂammatory drug (NSAID), and 
selectively inhibits COX-2. Comparing with coxibs, meloxicam shows 
less cardiovascular toxicity; however, anti-tumor efﬁcacy has not been 
proved in clinical settings. The correlation between overexpression of 
COX-2 and chemotherapeutic response is also still controversial.
Methods: Eligibility criteria included stage IIIB/IV histologically or 
cytologically conﬁrmed non-small cell lung cancer, no prior chemo-
therapy, no current use of NSAIDs, PS = 0-1, and no urgent symptoms. 
Patients received oral meloxicam (150 mg) daily, and carboplatin 
(AUC 5) plus docetaxel (60 mg/m2) on day 1, every 3 weeks. Treat-
ment was continued until disease progression or toxicity. The primary 
endpoint was anti-tumor effect, with secondary endpoints including 
the safety. Calculated sample size was 45 patients (Simon’s two-stage 
minimax design). Tumor immunohistochemistry was performed for 
COX-2 and p27 in archival parafﬁn-embedded pre-treatment tumor tis-
sues. A semi-quantitative expression score was calculated on the basis 
of both percentage of positive tumor staining (COX-2 in cytoplasm, 
and p27 in cell nuclei) and staining intensity.
Results: From April 2005 to July 2006, a total of 50 patients (33 
males/17 females; median age, 65 years; ECOG PS, 0/1 = 24/26; tumor 
histology, adeno/squamous/other = 29/18/3; stage, IIIB/IV/recurrence 
= 16/32/2) were accrued and 47 patients were eligible. Partial response 
was 40% (95% CI 25-55%), stable disease was 38% (95% CI 23-
53%), and 19% had progressive disease. Grade 3/4 hematologic events 
included leukopenia (81%), neutropenia (96%), and thrombocytopenia 
(8%). Grade 3/4 non-hematologic events included hyponatremia (6%), 
anorexia (6%), fatigue (2%), angina (2%), skin rash (2%), and neuropa-
thy (2%). Febrile neutropenia occurred in 2 patients, and one patient 
developed pneumonia. Tumor tissues were available from 34 patients, 
and 32 samples were sufﬁcient for analysis. COX-2 expression corre-
lated with response rate (PR/SD+PD = 7/4 in high COX-2 score group, 
and 3/11 in low COX-2 score group; p<0.05, chi-square test). Response 
rate was not correlated with p27 status. There was no statistical associa-
tion between COX-2 and p27 expression.
Conclusions: Meloxicam added to carboplatin and docetaxel demon-
strated acceptable tolerability with encouraging activity in advanced 
NSCLC patients, especially in the patients with high COX-2 expres-
sion.
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Background: The efﬁcacy of PEM 500mg/m2 administered with 
vitamin B12 and folic acid (FS) in previously treated NSCLC has been 
established (Hanna 2004, N=571 [Study-W0]). The 500mg/m2 dose 
used in that study was selected based on the MTD for single-agent 
PEM without FS. Subsequent phase I studies in both western and 
Japanese study populations showed that single-agent PEM with FS was 
tolerated at doses of 900-1000mg/m2. The low toxicities in Study-W0 
and the tolerability of higher doses in the more recently completed dose 
escalation studies with FS led to studies comparing PEM 500mg/m2 to 
900 mg/m2 or 1000mg/m2 to determine whether a higher dose would 
provide additional efﬁcacy while maintaining an acceptable safety 
proﬁle. This work examines PEM ERRs and clinical study results from 
trials conducted in western and Japanese patients.
